Canaccord Genuity Reiterates Buy Rating on TriSalus Life Sciences, Inc. (TLSI)

Canaccord Genuity analyst William Plovanic reiterated a Buy rating and $11.00 price target on TriSalus Life Sciences, Inc. (NASDAQ: TLSI).

The analyst commented: 'TriSalus hosted an investor webcast that focused on the company’s opportunity in uterine fibroid embolization. The webcast featured Dr. Nicole Lamparello (Weill Cornell Medicine, New York-Presbyterian Hospital) and Dr. Francis Kang, MD (University Radiology Group, Rutgers Robert Wood Johnson University Hospital), who are two interventional radiologists that use TriNav for uterine fibroid embolization. The two KOL’s spoke about how TriNav XP (the newest catheter in the TriNav portfolio), which is designed specifically for expanded particle sizes and has a more flexible distal tip has enabled more efficient embolization procedures. While TriSalus’s core focus is on the liver opportunity, the KOL webcast demonstrates that its differentiated technology can be used outside of the liver as well, expanding its TAM to a company-estimated ~$2.5B opportunity. With strong feedback from the KOLs (who said that they had essentially no problem getting TLSI’s premium-priced technology through VAC and use TriNav in all their available cases), we continue to believe that TriSalus can continue its strong growth momentum."

For an analyst ratings summary and ratings history on TriSalus Life Sciences, Inc. click here. For more ratings news on TriSalus Life Sciences, Inc. click here.

Shares of TriSalus Life Sciences, Inc. closed at $4.42 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy